Risk factors
Whitehawk Therapeutics (WHWK) risk factors
Item 1A of every Whitehawk Therapeutics, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2024 10-K risk factors92 risks
Whitehawk is a preclinical biopharmaceutical company transitioning to a new antibody-drug conjugate pipeline after divesting its sole commercial product, FYARRO. The company faces significant ongoing net losses, relies on external capital to fund operations, and has never tested its ADC product candidates in humans.
Filed Mar 28, 2025